82 related articles for article (PubMed ID: 22931245)
41. [Bcl-2 antisense oligodeoxynucleotide enhances araninosyl cytosine-induced apoptosis of primary leukemia cells].
Lei XY; Zhang H; He DM
Ai Zheng; 2002 Dec; 21(12):1301-4. PubMed ID: 12520735
[TBL] [Abstract][Full Text] [Related]
42. Coformulated N-octanoyl-glucosylceramide improves cellular delivery and cytotoxicity of liposomal doxorubicin.
Veldman RJ; Koning GA; van Hell A; Zerp S; Vink SR; Storm G; Verheij M; van Blitterswijk WJ
J Pharmacol Exp Ther; 2005 Nov; 315(2):704-10. PubMed ID: 16040815
[TBL] [Abstract][Full Text] [Related]
43. Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic Acid.
Semple SC; Harasym TO; Clow KA; Ansell SM; Klimuk SK; Hope MJ
J Pharmacol Exp Ther; 2005 Mar; 312(3):1020-6. PubMed ID: 15525796
[TBL] [Abstract][Full Text] [Related]
44. Gene expression profile by inhibiting Raf-1 protein kinase in breast cancer cells.
Mewani RR; Tian S; Li B; Danner MT; Carr TD; Lee S; Rahman A; Kasid UN; Jung M; Dritschilo A; Gokhale PC
Int J Mol Med; 2006 Mar; 17(3):457-63. PubMed ID: 16465392
[TBL] [Abstract][Full Text] [Related]
45. Reversing drug resistance in the ovarian carcinoma cell line SKOV3/mdr1 in vitro by antisense oligodeoxynucleotides.
Pan L; Tong Y; Jin Y; Zhou S; Zhang Y; Yang X; Mao N
Chin Med J (Engl); 2001 Sep; 114(9):929-32. PubMed ID: 11780384
[TBL] [Abstract][Full Text] [Related]
46. Enhanced therapeutic effects of doxorubicin and paclitaxel in combination with liposome-entrapped ends-modified raf antisense oligonucleotide against human prostate, lung and breast tumor models.
Mewani RR; Tang W; Rahman A; Dritschilo A; Ahmad I; Kasid UN; Gokhale PC
Int J Oncol; 2004 May; 24(5):1181-8. PubMed ID: 15067340
[TBL] [Abstract][Full Text] [Related]
47. [Inhibitive effect of bcl-2 antisense oligodeoxynucleotide on Bcl-2 protein synthesis and cell proliferation in human laryngocarcinoma Hep-2 cells].
Jing H; Huang W; Qiu J
Zhonghua Er Bi Yan Hou Ke Za Zhi; 1998 Feb; 33(1):17-20. PubMed ID: 11498881
[TBL] [Abstract][Full Text] [Related]
48. Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy.
Paliwal SR; Paliwal R; Pal HC; Saxena AK; Sharma PR; Gupta PN; Agrawal GP; Vyas SP
Mol Pharm; 2012 Jan; 9(1):176-86. PubMed ID: 22091702
[TBL] [Abstract][Full Text] [Related]
49. Delivery of antisense oligodeoxyribonucleotide lipopolyplex nanoparticles assembled by microfluidic hydrodynamic focusing.
Koh CG; Zhang X; Liu S; Golan S; Yu B; Yang X; Guan J; Jin Y; Talmon Y; Muthusamy N; Chan KK; Byrd JC; Lee RJ; Marcucci G; Lee LJ
J Control Release; 2010 Jan; 141(1):62-9. PubMed ID: 19716852
[TBL] [Abstract][Full Text] [Related]
50. Effect of citral on the cytotoxicity of doxorubicin in human B-lymphoma cells.
Dangkong D; Limpanasithikul W
Pharm Biol; 2015 Feb; 53(2):262-8. PubMed ID: 25243873
[TBL] [Abstract][Full Text] [Related]
51. Programmable fusogenic vesicles for intracellular delivery of antisense oligodeoxynucleotides: enhanced cellular uptake and biological effects.
Hu Q; Shew CR; Bally MB; Madden TD
Biochim Biophys Acta; 2001 Sep; 1514(1):1-13. PubMed ID: 11513800
[TBL] [Abstract][Full Text] [Related]
52. Delivery of c-myb antisense oligodeoxynucleotides to human neuroblastoma cells via disialoganglioside GD(2)-targeted immunoliposomes: antitumor effects.
Pagnan G; Stuart DD; Pastorino F; Raffaghello L; Montaldo PG; Allen TM; Calabretta B; Ponzoni M
J Natl Cancer Inst; 2000 Feb; 92(3):253-61. PubMed ID: 10655443
[TBL] [Abstract][Full Text] [Related]
53. Antisense oligodeoxynucleotide directed against c-myb has anticancer activity and potentiates the antiproliferative effect of conventional anticancer drugs acting by different mechanisms in human colorectal cancer cells.
Abaza MS; Al-Attiyah RJ; Al-Saffar AM; Al-Sawan SM; Moussa NM
Tumour Biol; 2003; 24(5):241-57. PubMed ID: 15001837
[TBL] [Abstract][Full Text] [Related]
54. Efficient transfer of intact oligonucleotides into the nucleus of ligament scar fibroblasts by HVJ-cationic liposomes is correlated with effective antisense gene inhibition.
Nakamura N; Hart DA; Frank CB; Marchuk LL; Shrive NG; Ota N; Taira K; Yoshikawa H; Kaneda Y
J Biochem; 2001 May; 129(5):755-9. PubMed ID: 11328598
[TBL] [Abstract][Full Text] [Related]
55. Antisense inhibition of IGF receptor expression in HaCaT keratinocytes: a model for antisense strategies in keratinocytes.
White PJ; Fogarty RD; Werther GA; Wraight CJ
Antisense Nucleic Acid Drug Dev; 2000 Jun; 10(3):195-203. PubMed ID: 10905556
[TBL] [Abstract][Full Text] [Related]
56. Massive and selective delivery of lipid-coated cationic lipoplexes of oligonucleotides targeted in vivo to hepatic endothelial cells.
Bartsch M; Weeke-Klimp AH; Meijer DK; Scherphof GL; Kamps JA
Pharm Res; 2002 May; 19(5):676-80. PubMed ID: 12069172
[TBL] [Abstract][Full Text] [Related]
57. Targeted delivery system for antisense oligonucleotides: a novel experimental strategy for neuroblastoma treatment.
Brignole C; Pagnan G; Marimpietri D; Cosimo E; Allen TM; Ponzoni M; Pastorino F
Cancer Lett; 2003 Jul; 197(1-2):231-5. PubMed ID: 12880987
[TBL] [Abstract][Full Text] [Related]
58. HER-2-targeted antisense oligonucleotide results in sensitization of head and neck cancer cells to chemotherapeutic agents.
Rait AS; Pirollo KF; Ulick D; Cullen K; Chang EH
Ann N Y Acad Sci; 2003 Dec; 1002():78-89. PubMed ID: 14751825
[TBL] [Abstract][Full Text] [Related]
59. Liposome-coated nano doxorubicin induces apoptosis on oral squamous cell carcinoma CAL-27 cells.
El-Hamid ESA; Gamal-Eldeen AM; Sharaf Eldeen AM
Arch Oral Biol; 2019 Jul; 103():47-54. PubMed ID: 31132617
[TBL] [Abstract][Full Text] [Related]
60. Stabilized lipid coated lipoplexes for the delivery of antisense oligonucleotides to liver endothelial cells in vitro and in vivo.
Bartsch M; Weeke-Klimp AH; Hoenselaar EP; Stuart MC; Meijer DK; Scherphof GL; Kamps JA
J Drug Target; 2004; 12(9-10):613-21. PubMed ID: 15621687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
